Cardiac Valve Market Summary
As per Market Research Future Analysis, the Global Cardiac Valve Market was valued at USD 7.7 Billion in 2023 and is projected to grow from USD 8.20 Billion in 2024 to USD 12.7 Billion by 2032, with a CAGR of 5.62% during the forecast period. The increasing burden of valvular heart disease and sedentary lifestyles are key drivers of market growth. The rise in demand for minimally invasive surgeries and advancements in heart valve technology further enhance market expansion. However, high costs and alternative treatment options pose challenges. The market is significantly influenced by the growing prevalence of aortic stenosis and the increasing number of transcatheter aortic valve replacement (TAVR) procedures, which have surpassed traditional surgical methods.
Key Market Trends & Highlights
Key trends driving the Cardiac Valve market include advancements in technology and increasing disease prevalence.
- Heart valve disease affects approximately 5 million Americans annually.
- Rheumatic heart disease impacts 39 million people globally.
- The North America Cardiac Valve Market held 45.80% market share in 2022.
- The hospital & clinics segment dominated the market in 2022 due to increased procedures.
Market Size & Forecast
2023 Market Size | USD 7.7 Billion |
2024 Market Size | USD 8.20 Billion |
2032 Market Size | USD 12.7 Billion |
CAGR | 5.62% |
Major Players
Major players include Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, LivaNova PLC, Abbott, CryoLife, Inc., On-X Life Technologies, Inc., Colibri Heart Valve, JenaValve Technology, Inc., and TTK HealthCare.